August 27, 2014: These have been good times for the biotech industry. According to Ernst & Young, industry revenue jumped 10 percent last year to almost $100 billion while R&D spending climbed 14 percent (and a very strong 20 percent in the U.S.)—a trend that looks likely to continue into this year.
August 26, 2014: Biogen Idec announced that Donald Johns, M.D., has joined the biopharmaceutical company to serve as vice president. Johns is expected to head the amyotrophic lateral sclerosis Innovation Hub of the Cambridge-based company.
August 26, 2014: Pfizer and Merck announced a clinical trial collaboration to test Merck's Investigational Anti-PD-1 Antibody Pembrolizumab and Pfizer’s Crizotinib (XALKORI®) in combination for patients with ALK-positive advanced or metastatic non-small cell lung cancer.
August 25, 2014: According to the Radford Trends Report, 20 percent of companies plan to increase their hiring by five percent. Also, 8.8 percent will increase by 10 to 15 percent and 12.6 percent of companies plan to increase by 15 percent.